(d) whether its sales in terms of product units is also declining and if so, what has been the decline during the past three years?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) No, Sir.

(b) The estimated accumulated losses of IDPL as on 31.3.93 are Rs. 623 crores. The company has, in compliance with the provisions of the Sick Industrial Companies (Special Provisions) Act, 1985, made a reference to the Board for Industrial and Financial Reconstruction (BIFR). A Rehabilitation Plan is under preparation. It would be premature to indicate the loss of 1993-94 at this stage.

(c) There is no such proposal under consideration at present.

(d) The details in respect of sales of major key bulk drugs during the last three years are given in the Statement enclosed. (*See* below) The statement shows mixed trends with the sales of some items going up and of the others coming down.

Statement

Sales of major key bulk drugs during 1990-91, 1991-92 *and* 1992-93.

PRODUCTS	UNIT	1990-91	1991-92	1992-93
Penicillion	MMU	270.5	243.7	381.2
Tetracycline	MT	61.8	27.5	15.0
Oxytetracycline	MT	41.5	60.9	72.9
Vitamin B1	MT	67.7	76.6	55.3
Vitamin B2	MT	21.5	18.2	19.8
Folic Acid	MT	3.5	4.0	6.41
Niacinamide	MT	44.9	83.1	91.3
Acetazolamide	MT	6.0	3.2	7.5
Barbital Sodium	MT	..	0.8	5.51

Controlling the prices of drugs

1901. SHRMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1986 given in the Rajya Sabha on 11-3-93 and state:

(a) whether it is a fact that the material cost for Cifran, Calmpose, Evion, Daonil and trexyl is highly inbated and that Government have not scrutinised these costs;

(b) whether Government would ensure the sale of Trexyl at Rs. 2.05 per tablet when it is a single anti-hretamine and heavy foreign exchange is being passed outside the country; and

(c) what steps have been taken to conduct enquiry into the affairs of producers of Trexyl?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) As already stated in answer to question No. 1986 dated 11.3.93, all these formulations are outside price control. If there is an exorbitant increase in the prices of the non-scheduled formulation, over the earlier

prevailing price or post manufacturing, expenses charged are unreasonably high, the concerned manufacturers are asked to justify and if justification is not reasonable an attempt is made to prevail upon them to reduce the price to the extent possible.

Price fixation of and T.B. drugs

1902. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that cases of wrong price fixation in case of anti-T.B. bulk drugs and getting data for cost study from companies like Ranbaxy have not been followed up;

(b) in what manner these companies are overcharging the prices of their bulk drugs and formulations and the reasons for not taking action against them;

(c) what is the reason for M/s Hoechst and M/s Glaxo keeping a number of their bulk drugs and formulations out-side price control; and

(d) whether compliants have been ignored and investigations in this area have not been held, if so, the reasons therefore?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) There is no case of wrong price fixation in case of Anti-T.B. drugs. To the extent information available, M/s. Ranbaxy does not manufacture Anti-T.B. drugs like Ethambutol, Rifamicin, Isoniazied, Thraoetazone, Sod PAS etc.

(b) Does not arise.

(c) to (d) Decision in regard to productmix to be manufactured by any company including M/s Hoechst and M/s Glaxo is dependent upon the corporate policy of that company and Government cannot interfere in the matter.

Identification of products marketed without approval

1903. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 375 given in the Rajya Sabha on 25th February, 1993 and state:

(a) what is the fate of the hearing by the regular bench in the case of Carews and whether it is a fact that in 1984 the company submitted applications for all its products to the Assistant Development Commissioner (PI);

(b) whether it is a fact that even after a lapse of eight years Government have failed to identify the products which have been marked without price approval and also to fix responsibility on the concerned officers;

(c) what is the stage of the investigation relating to inter connection of this company with Hoechst/B.B. Group stands and the reason for non-completion of investigation in spite of lapse of over three years; and

(d) whether it is a fact that M/s. Carews is merely a sham created to evade taxes and make money by tampering with purchase of raw materials?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) The matter is still pending in the Court. As per the record available no application for price fixation was submitted by M/s. Carews in 1984.

(b) For three formulations viz. (i) Combiflam Tabs; (ii) Carelgin Tabs. and (iii) Aleagel Tabs., prices were fixed on the basis of application submitted by M/s. Carews in 1986. To the extent information is available, for the other three products namely (i) Carovin Tonic; (ii) Carewvit Liquid; and (iii) Trimazol Tabs, the company does not appear to have obtained any price approval from the Government.

(c) The Department of Company Fertilizers has submitted a proposal to